Earnings call
Jagsonpal Pharmaceuticals Q2 FY27 earnings call: Jagsonpal expects quarterly revenues to cross INR100 crores in Q3 of the current year and is on track for its mission of INR500 crores by 2028
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
Jagsonpal expects quarterly revenues to cross INR100 crores in Q3 of the current year and is on track for its mission of INR500 crores by 2028. Jagsonpal's growth accelerated to closer to 10% over the last 6 months, on the back of strong growth in its power brands while it invested disproportionately in new launches, higher growth areas and organization building.
The numbers management gave
Results
- Jagsonpal's growth accelerated to closer to 10% over the last 6 months, on the back of strong growth in its power brands while it invested disproportionately in new launches, higher growth areas and organization building.
Show source
Over the period, we have been able to accelerate our growth to now closer to 10%, on the back of strong growth in our power brands even as we invested disproportionately in new launches, in higher growth areas as well as organization building.
- Over the last 6 months, Jagsonpal's organic growth was 9.3%.
Show source
In the first 6 months, our organic growth has been 9.3%.
- Jagsonpal's EBITDA margins in H1 were 22.9%, up 40 bps, even after enhanced investments.
Show source
Our EBITDA margins in H1 were at 22.9%, up 40 bps, even after these enhanced investments.
- Jagsonpal's MR productivity was already up by around 10%, and its target is to go beyond its productivity threshold.
Show source
Early results are encouraging, with MR productivity already up by around 10%, and our target is to go beyond the threshold of productivity that we aspire for.
- Jagsonpal's standalone gross margin was 64.1% for the quarter and 64.7% for the half year, an improvement of close to 70 bps over the corresponding previous period.
Show source
Standalone gross margin stood at 64.1% for the quarter, whereas it was 64.7% for the half year, indicating an improvement of close to 70 bps over the corresponding previous period.
- Jagsonpal's standalone EBITDA margin for the quarter was 22.7%, broadly stable despite planned advance investments in people, marketing and medical inputs, while its consolidated EBITDA margin was 19.3%.
Show source
Standalone EBITDA margins for the quarter remained broadly stable at 22.7%, despite planned advance investments in people, marketing, and medical inputs, as indicated by Manish in his speech, while our consolidated EBITDA margin stood at 19.3%.
Show 6 more statements
Results
- Jagsonpal's standalone PAT was INR13 crores and consolidated PAT was INR12 crores, with margins of 15.5% and 12.8%, respectively.
Show source
At the bottom line, standalone PAT stood at INR13 crores, while consolidated PAT was INR12 crores, with a margin of 15.5% and 12.8% respectively.
- Jagsonpal Pharmaceuticals’ hospital business is rate-driven and contract-driven, with contracts typically taken for a year; price pressures over the last 12 months, especially on APIs, were addressed through supply-chain work and more efficient procurement, with corrective actions expected to reflect in financials from Q4 onwards.
Show source
The corrective actions that we have taken will start reflecting in the financials only from Q4 onwards because we have done a lot of work on the supply chain, better procurement and more efficient procurement and whatnot.
- Jagsonpal's branded prescription growth is in excess of double digit.
Show source
So on the branded prescription side, in fact, our growth is in excess of double digit.
Money and capital
- Jagsonpal had a cash balance of INR135 crores and is confident of accelerating its journey through meaningful and accretive transactions.
Show source
With the cash balance of INR135 crores and a track record of successful inorganic growth, we are confident of fast tracking this journey through meaningful and accretive transactions.
- Jagsonpal maintained a cash and bank balance of over INR135 crores and generated net operating cash of INR25 crores at a consolidated level during first half of FY27, despite enhanced dividend payout and ongoing acquisition investments.
Show source
Despite the enhanced dividend payout and our ongoing investments in acquisitions, the company continues to maintain a strong cash position with cash and bank balance of over INR135 crores, and we continue to generate net operating cash of INR25 crores at a consolidated level during first half of FY27.
- Jagsonpal structured its transactions to derisk itself and retain the strength of its balance sheet for further initiatives.
Show source
We also take pride in the way we have been able to structure the transactions, which derisks us and retains the strength of our balance sheet for further initiatives.
What it expects ahead
What management expects
- Jagsonpal expects quarterly revenues to cross INR100 crores in Q3 of the current year and is on track for its mission of INR500 crores by 2028.
Show source
We expect quarterly revenues to cross INR100 crores in Q3 of the current year, and we are on track of mission INR500 crores by 2028.
- Jagsonpal expects EBITDA accretive growth in quarter 3.
Show source
I assure you that we will see EBITDA accretive growth in quarter 3.
- Jagsonpal is confident of growing faster than its 9.3% growth over the last 6 months, citing investments already made in products, new launches and people.
Show source
We are certainly confident of growing faster.
- Jagsonpal's INR500 crores target over the next 2 years is to be driven by pure organic growth, with nothing beyond that.
Show source
So it's a pure organic growth that will lead to these numbers over next 2 years, nothing beyond that.
- Jagsonpal committed to enhanced growth and EBITDA growth in quarter 3.
Show source
So I think going forward, I already committed to you that quarter 3, you will see a much better and enhanced, and more importantly, an EBITDA growth.
- Jagsonpal is committed to delivering its INR500 crores vision with its current basket and without further acquisitions, driven purely by organic growth from its current product profile.
Show source
As far as the numbers are considered, we are committed to this INR500 crores vision, which we are sure to deliver with our current basket and without considering any further acquisitions into this INR500 crores number.
Show 15 more statements
What management expects
- Jagsonpal is confident of reaching the 22% mark again on a blended basis.
Show source
Manish Gupta: So I think on a blended basis, we are confident of reaching the 22% mark again.
- Jagsonpal is very confident of over 22% EBITDA margin for the collective business.
Show source
So collectively, we are very confident of over 22% EBITDA margin for the collective business.
- Jagsonpal is looking at growth upward of 1.5x of IPM growth.
Show source
And as promised, we are looking at upward of 1.5x of the IPM growth, Sajal.
- Jagsonpal has started work on a 5-year journey and may return with a more granular and detailed road map.
Show source
That work has already started, and we will possibly come back to you with much more granular and detailed, I will say, road map for a 5-year journey as well.
- Jagsonpal is focused on hitting INR500 crores by 2028 calendar year purely organically, with no inorganic play.
Show source
Currently, we are 100% focused on what is visible for us, relatively much closer to us, which is 2028 calendar year, Sajal, for hitting that INR500 crores and purely organically, no inorganic play within this.
- Jagsonpal is targeting quarterly revenue crossing INR100 crores in quarter 3, which it says means growth in excess of 1.5x of expected pharma industry growth in quarter 3.
Show source
So I'm not providing you a very long term this thing, but quarter 3, as we had already committed, we are targeting a 3-digit number of crossing INR100 crores, and that certainly means that our growth will be in excess of 1.5x of the expected pharma industry growth in quarter 3.
- The company is focused on gynecology, orthopedics, dermatology and critical care for its INR500 crores vision; it wants to reduce dependence on acute therapy and will evaluate opportunities in the chronic segment.
Show source
Amrut Medhekar: So as I mentioned, sir, for this INR500 crores vision, we are currently focused purely on these 4 therapy areas, which I mentioned: gynec, ortho, derma, and obviously critical care, which is newly added.
- The company expects its standalone margins to improve year-on-year by 50 to 75 bps based on product mix and price increases.
Show source
We are close to 65% currently, and Page 13 of 16 Jagsonpal Pharmaceutical Limited October 29, 2026 this number should improve year-on-year through 50 to 75 bps based on product mix, price increases and whatnot.
- Jagsonpal Pharmaceuticals’ 10 brands constitute roughly 60% of its business and will largely contribute towards growth; the company intends to make the majority of these brands leaders in their respective therapy areas.
Show source
Amrut Medhekar: Currently, the top 10 brands, which I mentioned in my opening statement, those brands will contribute majority for the EBITDA.
- New products contribute 2.3%, 2.5% of Jagsonpal Pharmaceuticals’ overall growth and their contribution will only go up from here.
Show source
Currently, it is 2.3%, 2.5% of our overall contribution of growth.
- Jagsonpal's hospital business will remain a lower-margin business but will become far more profitable than it is today.
Show source
It will stay a lower margin business, but it will become far more profitable than where it is today.
- Jagsonpal Pharmaceuticals’ Aequitas business margins will improve from where the business is initiating, but the improvement will be slower and will not match JPL gross margin.
Show source
So that will follow its own margin trajectory, will certainly improve from where we are initiating the business from, but that journey will be far slower and it will nowhere match with JPL gross margin at any point of time.
- Jagsonpal Pharmaceuticals’ absolute value growth will be driven by existing brands, while new brands may take multiple quarters or multiple years to build into scaled brands.
Show source
But in terms of real growth, absolute value growth, it will be driven by the existing brands.
- The company expects external audit and market research data to merge in a couple of quarters.
Show source
But suffice it to say that we are seeing, I would say, merging of the 2 data hopefully in a couple of quarters.
- Jagsonpal is confident that its initiatives will support business performance in Q3 and contribute sustainable growth over the longer term. Replaced by a later filing.
Show source
We are confident that these initiatives will support business performance in Q3 and continue to contribute sustainable growth over the longer term.
What it is building and selling
Segments
- Jagsonpal Pharmaceuticals’ Aequitas business has much lower margins because it is a critical care, hospital and price-driven business.
Show source
The margins in Aequitas business are much, much lower given the nature of business since it's a critical care business, hospital business and whatnot.
Deals and partners
- Jagsonpal's JPL hospital team is being built to cross-sell its portfolio into Aequitas network, opening institutional tenders and first prescription opportunities.
Show source
We are building the JPL hospital team so that we can cross-sell our portfolio into Aequitas network, which opens institutional tenders and first prescription opportunities for us.
Everything else said on the call
What management stressed
- Jagsonpal directed its brand money into products and therapies with the strongest growth visibility while keeping a few promising launches every quarter. Replaced by a later filing.
Show source
We have also sharpened where we put our brand money, directing into the products and therapies with the strongest growth visibility while keeping us a few promising launches every quarter.
Group structure
- Jagsonpal completed 2 acquisitions over the last 6 months, providing additional growth levers.
Show source
We completed 2 acquisitions, which provide us now with additional growth levers.
- Jagsonpal's wellness portfolio became part of its portfolio from 1st October, and it prepared for integration during Q2.
Show source
While the wellness portfolio became part of JPL portfolio from 1st October, we fully prepared ourselves for the same in Q2 itself for an effective day 1 integration.
- Following completion of the wellness portfolio acquisition and discharge of part consideration during October '26, Jagsonpal is focused on leveraging combined commercial capability and realizing business synergies.
Show source
Following the completion of wellness portfolio acquisition and the discharge of part consideration during October '26, our focus is now on leveraging combined commercial capability and realizing business synergies.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Ankur Kumar: Got it, sir. And sir, on the margin side, what are our estimates for when we are reaching this INR500 crores? Because I think standalone is still quite good in terms of 20-plus margins. And -- but in consol side, this quarter, I think there is not much contribution from subsidiary. Well, there is revenue contribution, but profit side, it's not much?
Answer, manish gupta
Manish Gupta: So I think on a blended basis, we are confident of reaching the 22% mark again. Standalone, obviously, will be much higher. But you would appreciate that hospital business is a lower margin business. It will stay a lower margin business, but it will become far more profitable than where it is today. So collectively, we are very confident of over 22% EBITDA margin for the collective business.
Question
Ankur Kumar: Got it, sir. And sir, in Q3 side, you are estimating INR100-plus crores revenue. So can margin go to 20% from Q3 onwards or like it will take time? How are we thinking on that, sir?
Answer, manish gupta
Manish Gupta: Q3 will definitely deliver more than 22%. It's generally Q4, which is a bit of a drag in India, which pulls down the margin. But otherwise, on the 3 quarters, we are quite confident -- okay, I probably -- yes, on a consolidated basis, we'll be very close to 22%, if not more.
Question
Ankur Kumar: 22% on the consol side you mean, as in we will be able to improve margins on the hospital business and the other business?
Answer, manish gupta
Manish Gupta: Yes, collectively. Individually, hospitals won't reach those levels, let's be clear about it. But yes, collective margins will still be in excess of 22% or thereabout.
Question
Ankur Kumar: Got it, sir. Sir, last question will be on the stand side, you have given great details in terms of products. So what is our expansion strategy? Are we looking for adding more products or like we are looking for more expansion in these existing products, sir?
Answer, amrut medhekar
Amrut Medhekar: So in quarter 3, as I mentioned for the acquired business of Aequitas, we have planned a new brand, which should possibly get commercialized in November end, and go-to-market can be in the first week of December. But other businesses, other vertical therapies, we don't have any plans of any new product launches in quarter 3. We have planned some launches in quarter 4. So that's about the new product. And therefore, as far as expansion is considered also, we are not planning any manpower addition to our current budgeted numbers. Page 6 of 16 Jagsonpal Pharmaceutical Limited October 29, 2026 Moderator: Our next question comes from the line of Sajal Kapoor with Antifragile Thinking.
Question
Sajal Kapoor: Yes. And from Q3, Amrut, Group Pharma comes in through a BTA, right? So it will sit inside a standalone and standalone then stops being a clean organic number. So my humble request is so that we as investors can track both organic and inorganic separately, starting with the Q3 deck, will you be kind enough to introduce a separate line for organic growth?
Answer, manish gupta
Manish Gupta: Yes. I think that, see, we have been always very open in our communication and that information will be provided in terms of split between organic and inorganic growth. It will not be like a separate line item, but it will be part of the commentary.
Answer, amrut medhekar
Amrut Medhekar: So, Sajal, just to add to what Manish said, we'll certainly add the -- for the transparency sake, we'll certainly add the numbers as you seek. However, those numbers will be split into 2 parts because Group has been present only in 6 states. So we will give you apple-to-apple, what is happening to those 6 states vis-a-vis the state outside of those 6 geographies because though outside those 6 geographies, it's a technically ground 0 launch for us, right? So you'll appreciate that will be a hardcore earnings for each of the MRs who is outside those 6 states. So that will be organic for the JPL. And within those 6 states, obviously there will be some base, which is roughly around INR1.75 crores of the established 2 brands that we are talking about. That will certainly tell you as to how much they are contributing.
Answer, amrut medhekar
Coming to your point number 1, that we have been always talking about beating the market performance. Yes, the numbers, as Manish alluded to in the beginning, that we have been flattish at around 10% quarter 1 also and quarter 2 also. Branded pure-play prescription is upward of 10 percentage, contributing around 11%, 11.5%. However, this is also lower than my own expectations. And trust me, those numbers will completely change going forward in quarter 3. We know that the trajectory has been better as compared to past. So it has moved from a single digit to at least double digit.
Answer, amrut medhekar
And now we are certainly set up with a platform to take it forward. And as promised, we are looking at upward of 1.5x of the IPM growth, Sajal.
Question
Sajal Kapoor: Right. No, that's helpful, team. And to both of you, so you have skin in the game, right? I mean if the stock performs, if the organization does better, you are the direct beneficiary yourself. So you have "Ownership-led soul in the game," as they say. Page 7 of 16 Jagsonpal Pharmaceutical Limited October 29, 2026 With that context, projecting 5 years out, what kind of Jagsonpal will make you feel a tad disappointed that this is not the kind of Jagsonpal Pharma we envisaged and we have not delivered against our own sort of expectations, forget shareholders. I'm just trying to understand that kind of vision for Jagsonpal Pharma 5 years out. Nothing about next quarter or next yea
Answer, amrut medhekar
Amrut Medhekar: Completely appreciate, Sajal. As I think Manish has mentioned it twice in his opening statement that we are completely focused currently on our INR500 crores vision of Mission 2028. I understand that cannot be called as an LRP or a long-range planning. That work has already started, and we will possibly come back to you with much more granular and detailed, I will say, road map for a 5-year journey as well. Currently, we are 100% focused on what is visible for us, relatively much closer to us, which is 2028 calendar year, Sajal, for hitting that INR500 crores and purely organically, no inorganic play within this.
Answer, manish gupta
Manish Gupta: And Sajal, I'll just add on to this. This playbook can change when we are talking of 5 years because we have multiple paths to decide. Currently, we are a singular market company that has its strengths and that also has its own challenges. So we are obviously in discussion with our promoters and shareholders, the critical shareholders on what could be the next 5-year journey. And that may entail us beyond what we are doing today. So we will come back to you once we are ready with the plan, but there may be certain broadening of strategy as we go along.
Question
Sajal Kapoor: Sure, Manish. And lastly, just from a business model perspective, there are some smaller companies in India. So maybe I can name RPG Life for the context here. They are also doubling down on API because they believe that backend and owning the backend is very relevant and increasingly important from an exports or outside India perspective. Currently, I know our focus is purely domestic. And in that context, there are some very good CMOs in India where you can just leverage manufacturing and outsource all of it. But in grand scheme of things, if we have to grow bigger and even enter emerging markets in Africa or elsewhere, how do you see the backend from a business model perspec
Answer, manish gupta
Manish Gupta: Yes. Sajal, that's what I was alluding to when I gave my comments after Amrut. That we are very clear on the next 2 year's journey. But if we were to take it further, which way to end because without manufacturing, you cannot do anything outside India, okay. Be it emerging markets or regulated markets and whether it is formulation manufacturing or API manufacturing, no doors are open unless you have something to do anything outside India. So that's a journey which we are yet to decide. We clearly have a clear plan for next 2 years, but we are in discussion with our promoters, as I mentioned, and our Board in terms of taking the next steps because fortunately, in terms of where we are, both in terms of capital as also capital Page 8 of 16 Jagsonpal Pharmaceutical Limited October 29, 2026 commitment, we have lots and lots of flexibility.
Answer, manish gupta
And there are a fair bit of good assets available in this country in either of the direction we may choose to take. So we are definitely seized on the matter. We do not have a clear answer for you yet, but it will go one of the ways that you are potentially alluding to.
Question
Sajal Kapoor: No, that's perfect. That's perfect. And promoter-wise, Manish, we have one of the best promoters available in the country. So that should not be a problem. And I see yourself as a promoter as well. So I think, yes, promoter, we have got best-in-class and hopefully, with a little bit of luck, we should be able to get there. But yes, thank you for all the responses, and all the very best. That’s all.
Answer, manish gupta
Manish Gupta: So I'll partly respond to it and then Amrut will give more details. And this is consistent to what I have always said. Any acquisition is a bit of strategy and also a bit of opportunity. You may wish for a lot of things to be done, but it has to fit your strategy and also a price that you're willing to pay for it. So yes, I'm not at all suggesting that we are not open to acquisitions in gynae and ortho where we are already strong. Those are certainly desirable, but there were very few opportunities or very expensive opportunities in that area. We did look at some, but clearly, they were outside our scope of what we want to do.
Answer, manish gupta
Now coming to specific these 2 assets, Amrut, if you can give a clear rationale for the same.
Answer, amrut medhekar
Amrut Medhekar: Thank you so much, Mr. Damania. First part -- let me start with Aequitas. For Aequitas, the clear thinking was that if you look at historically, the legacy of Jagsonpal had always been into the trade channel, which is doctors sitting outside the hospitals. And we had not been present in the hospital segment. However, the industry has moved far beyond from almost 2% contribution to in excess of around 11.5% contribution purely coming from the hospital -- corporate hospital chains. I'm not considering here public hospitals or government hospitals or dispensaries. Pure-play corporate chains are now contributing in excess of 11.5%.
Answer, amrut medhekar
So that's a huge surge, and that's the area that we wanted to tap immediately before it becomes too late for us. And Aequitas provided us that handle, that entry point, because it is a niche player across majority of the corporate hospital chains. Page 9 of 16 Jagsonpal Pharmaceutical Limited October 29, 2026 So that access we have got now. Besides they doing their own volumes, we'll be able to cross- sell some of the JPL brands, Jagsonpal brands, into that channel. So that's answer to your question number one. Question number two was regarding Group Pharma opportunity. Group Pharma has been a very interesting opportunity for us because what we always look at is in terms of the legacy of that organization, the well-entrenched distribution and doctor relationships for at least 1 or 2 good brands in that organization.
Answer, amrut medhekar
And I think that was clearly an opportunity area because, one, it's a very old organization, almost similar culturally vis-a-vis Jagsonpal. So there was no cultural integration issues or even in terms of, I will say, people issues because similar kind of pay structures and around structures were existing. So it was an easier play, easier integration process for us. Number three, very interestingly it provided a geographical expansion opportunity outside the 6 states where Group Pharma does not exist today in these businesses, these brands. So I think this was more of expansion opportunity for us in terms of these 2 brands getting scaled up. And last and most important, even the margins were similar in nature for Group Pharma as well as for Aequitas. And lastly, it's a co-prescription business.
Answer, amrut medhekar
So hopefully, the scale-up will be much easier for us to do in a strength area of Jagsonpal. So I hope I answered, Mr. Damania, both your part of question.
Question
Mihir Damania: Yes. Very clear. My second question is more on -- so if you look at the IPM growth, seems like a bulk of the growth is also coming from, let's say, new product introductions into the market. Now you alluded that you are willing to launch a few new products, but have you thought about maybe in-licensing some of the brands from, let's say, an MNC or like any other competitor? It's not like an acquisition strategy, but something where you think you can do a much better job than the brand owners currently do.
Answer, amrut medhekar
Amrut Medhekar: Yes, yes. So Mr. Damania, we had always been evaluating those opportunities. However, as Manishji said, that ultimately it depends on what are you ready to pay because most of these in- licensing opportunities, those provide scale to you, but at a very, very low margin. So we have been carefully evaluating those opportunities, and we are still in the process of evaluating 1 or 2 opportunities, which may eventually fructify. We do not know which way it will finally move, but we are in active discussion is what I can say right now. Secondly, in terms of new product successes, I think if you look at the split of our contribution or growth levers, which is element of price growth, volume growth and new products, we are completely aligned with the pharma industry in India. So our contribution of new products is equally good as good as any other therapy company or any other IPM contributor.
Question
Mihir Damania: Got it. And my last question, I think a lot of participants have kind of pushed about your organic standalone growth. Let's say in the next couple of quarters are more -- or let's say in the next Page 10 of 16 Jagsonpal Pharmaceutical Limited October 29, 2026 couple of quarters, do you expect your standalone revenue growth to be in line or better to the IPM growth rate? Is that a fair assumption to...
Answer, amrut medhekar
Amrut Medhekar: Yes. So I'm not providing you a very long term this thing, but quarter 3, as we had already committed, we are targeting a 3-digit number of crossing INR100 crores, and that certainly means that our growth will be in excess of 1.5x of the expected pharma industry growth in quarter 3.
Answer, amrut medhekar
Amrut Medhekar: It is similar to Jagsonpal, sir.
Answer, amrut medhekar
Amrut Medhekar: These are 2 different therapy brands. Indocap is primarily a GP physicians, and orthopaedic and rheumatology. These are the top of 4 specialties who currently contribute to the brand. It had its own challenges because it has been a legacy brand, very old molecule. We are trying to make some innovation in terms of packaging as well as in terms of broadening its current use, and that's taking little time, but hopefully we'll see those outcomes happening because the first part of the innovation is already under -- I'll say, under good execution and go- to-market should happen somewhere, I think, November. So we will see that revival of the brand, sir. And the second brand that you mentioned is about Equirex.
Answer, amrut medhekar
This product belongs to a category which is currently kind of not freely sold. It comes under restricted. It's part of NRx portfolio, and therefore, we can't do much in terms of availability and sales of the brand. We can only work on the prescription generation, which the team is currently doing. And we are going to double-down our efforts to ensure that this brand also comes to a double-digit growth.
Answer, manish gupta
Manish Gupta: So just to add on, we do have clear plans on Indocap. And coincidentally, it has not de-grown, but it has grown slower than the market. It's 4.5%.
Answer, amrut medhekar
Amrut Medhekar: 1% less, 1% less than the market, sir.
Answer, manish gupta
Manish Gupta: Yes, yes. But on Equirex, yes, it will be a bit of market determined growth purely on account of NRx. Urmish Shah: So sir, when you say that the first phase of innovation will bear results in November, so can we expect in the -- at least in the next financial year that these figures may be improving? Page 11 of 16 Jagsonpal Pharmaceutical Limited October 29, 2026 Amrut Medhekar: Yes, sir.
Answer, amrut medhekar
Of course. I mean all the efforts are on to do that. And I'm very confident that we'll see at least part results in quarter 3 itself, even though we may have just 45 days of the quarter available for us, yes.
Show 2 more questions
Question
Urmish Shah: Right. And sir, one question on the product mix. Now since we have had 2 acquisitions in terms of Aequitas and Group, going 2 years down the line, 3 years down the line and with our vision of INR500 crores, what would be the product mix that you envisage in terms of contribution to the top line?
Answer, amrut medhekar
Amrut Medhekar: Currently, we continue to be in the similar therapy area. So only one area which was clearly missing out from Jagsonpal was hospitals and critical care portfolio, which has got added. And with that, we have 2 more big specialty, so to say, which got added. One is critical care specialists themselves, and second is infectious disease specialists in the hospital segment. So these 2 got added. Otherwise, we remain focused on our key therapies, which is gynaecology. Purely from the contribution point of view, this is the largest contributor for Jagsonpal, followed by orthopaedics and then followed by dermatology.
Question
Thank you, sir. My another question was that we have some very good managerial bandwidth in terms of Amrut sir and Manish sir. So beyond INR500 crores, what are the brands or kind of therapy areas in chronic or sub-chronic that we are targeting to make some big brands like the legacy ones from JPL?
Answer, amrut medhekar
Amrut Medhekar: So as I mentioned, sir, for this INR500 crores vision, we are currently focused purely on these 4 therapy areas, which I mentioned: gynec, ortho, derma, and obviously critical care, which is newly added. Beyond that, we are exploring opportunities because eventually we want to build an organization which is focused on sub-chronic and chronic segment. We want to reduce our dependence on the acute therapy, because those are more cyclical in nature and does not bring the sustainable and predictable numbers for us. So chronic and sub- chronic is going to be our focus area, and therefore, any opportunity coming our way into chronic segment, we will certainly evaluate. But as mentioned earlier, currently the kind of valuation that we are seeing for those kind of targets is certainly not what we would like to pay currently.
Answer, vansh gupta
Vansh Gupta: Sir, last quarter, we had spoken about brand premiumization in our portfolio, which I believe the management had spoken of that would lead to higher gross margins. However, if I look at our gross margin on the standalone business, they have hovered around 64%, 65% for the last 8, 9 quarters. So could you please shed some light on what can be a sustainable gross margin for us going forward?
Answer, amrut medhekar
Amrut Medhekar: Your voice is little bit not audible, sir. If you can maybe just keep mic little away and go little slow.
Answer, manish gupta
Manish Gupta: So let me answer this. See -- and you will notice that we are presenting 2 sets of numbers. One is standalone and consolidated. I think our standalone margins because that is fundamentally a branded business for us, will be continuously improving. We are close to 65% currently, and Page 13 of 16 Jagsonpal Pharmaceutical Limited October 29, 2026 this number should improve year-on-year through 50 to 75 bps based on product mix, price increases and whatnot. The margins in Aequitas business are much, much lower given the nature of business since it's a critical care business, hospital business and whatnot. It's a price-driven business.
Answer, manish gupta
So that will follow its own margin trajectory, will certainly improve from where we are initiating the business from, but that journey will be far slower and it will nowhere match with JPL gross margin at any point of time. And the margin will be, of course, what will be presented in consolidated numbers.
Answer, manish gupta
Manish Gupta: On a consolidated basis, we should be closer to where we are in the Q2.
Answer, amrut medhekar
Amrut Medhekar: Obviously, the business is based on the existing brands. New brands will take their own sweet time because these are more trust and credibility based, which will take their own sweet time. And sometimes it is multiple quarters and sometimes it is multiple years also to build up a very scaled brand. So even though the trajectory looks very high in terms of percentage growth on the new brands because the scale looks very, very small. But in terms of real growth, absolute value growth, it will be driven by the existing brands.
Answer, amrut medhekar
Amrut Medhekar: Currently, the top 10 brands, which I mentioned in my opening statement, those brands will contribute majority for the EBITDA. Vansh Gupta: But there's no specific brand that we believe is going to help carry majority of the growth?
Answer, amrut medhekar
Amrut Medhekar: There is unlike many pharma businesses, we are not 2-brand or 1-brand driven organization. Our brands are almost of reasonable size across businesses and specialties. And therefore, that blend and mix will continue. However, we intend to make majority of these brands leaders into their Page 14 of 16 Jagsonpal Pharmaceutical Limited October 29, 2026 own respective therapy areas. And equally, we are pushing each of those therapy areas to build up for us. So I can't pinpoint that this 1 or 2 brands will constitute majority of growth. But I'm very sure that these 10 brands which constitute today roughly 60% of the business will largely contribute towards growth.
Answer, amrut medhekar
And of course, new products will only accelerate from here. Currently, it is 2.3%, 2.5% of our overall contribution of growth. It will only go up from here for new brands.
Answer, amrut medhekar
Amrut Medhekar: I can't comment on these external audits and market research as to how much lead and lag is there. But suffice it to say that we are seeing, I would say, merging of the 2 data hopefully in a couple of quarters. Currently, obviously it is little running faster than what we have primarily reflected for us. Secondaries are obviously growing in line.
Answer, manish gupta
It has rolled out the way exactly we had envisaged. So you have to bear in mind that hospital business is rate-driven contract-driven business. So contracts are taken for a year typically. You would also notice that there has been price pressures in the last 12 months, especially on the APIs and all front. These are critical care products you can't do much about. So nothing has been a surprise. The corrective actions that we have taken will start reflecting in the financials only from Q4 onwards because we have done a lot of work on the supply chain, better procurement and more efficient procurement and whatnot.
Questions about this call
- When was the Jagsonpal Pharmaceuticals Q2 FY27 earnings call transcript filed?
- Jagsonpal Pharmaceuticals filed the transcript with the exchange on 3 Nov 2026. This page is built from that transcript.
- What does this page list?
- 39 statements from the transcript across 7 topics, 25 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 12 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.